Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study

Introduction: Tirzepatide is recommended as a first-line injectable for people with type 2 diabetes (T2D), but there is a paucity of data on the use of basal insulin after tirzepatide in this population. This study aimed to evaluate glycemic control in people with T2D newly intensified with insulin...

Descripción completa

Detalles Bibliográficos
Autores: Ritzel, R, Davies, MJ, Hao, LC, Ji, LN, Lintu, MK, Mabunay, A, Mauricio, D, Bailey, T
Tipo de recurso: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Institución:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p21128
Acceso en línea:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21128
Access Level:acceso abierto
Palabra clave:Basal insulin
GIP
GLP-1 RA
Insulin glargine 300 U/ml
Real-world evidence
Tirzepatide
Type 2 diabetes
id ES_f9c63acfcdcbfdfc02985bb073d188be
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p21128
network_acronym_str ES
network_name_str España
repository_id_str
spelling Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T StudyRitzel, RDavies, MJHao, LCJi, LNLintu, MKMabunay, AMauricio, DBailey, TBasal insulinGIPGLP-1 RAInsulin glargine 300 U/mlReal-world evidenceTirzepatideType 2 diabetesIntroduction: Tirzepatide is recommended as a first-line injectable for people with type 2 diabetes (T2D), but there is a paucity of data on the use of basal insulin after tirzepatide in this population. This study aimed to evaluate glycemic control in people with T2D newly intensified with insulin glargine 300 U/ml (Gla-300) who had suboptimal HbA1c after treatment with tirzepatide. Methods: DELIVER-T was a retrospective analysis of the US Optum's Clinformatics (R) Data Mart from January 1, 2022 to August 31, 2024. People with T2D were included if they were insulin na & iuml;ve and were previously treated with tirzepatide and then intensified with Gla-300. The primary analysis (Gla-300 switch/add-on group) included all those with a HbA1c > 7.0% at baseline who either switched from tirzepatide to Gla-300 or who added Gla-300 to tirzepatide. The primary endpoint was the change in HbA1c levels from baseline to 6 months. Secondary endpoints included reaching HbA1c target < 7.0% and any hypoglycemia. Results: In total, 82 people had a HbA1c > 7.0% at baseline and were included in the primary analysis (Gla-300 switch/add-on group). The mean (SD) change in HbA1c from baseline to 6 months was - 1.3% (2.0; p = 0.0027) for the primary analysis (Gla-300 switch/add-on group). The proportion of participants reaching the target of HbA1c < 7.0% at 6 months was 26.8% (n = 22) for the primary analysis (Gla-300 switch/add-on group). No hypoglycemic events were captured in the database during the 6-month follow-up period. Conclusions: In insulin-na & iuml;ve people with T2D who had suboptimal HbA1c with tirzepatide, significant reductions in HbA1c and improvements in the percentage of people reaching HbA1c target of < 7.0% were observed with Gla-300. Infographic and video abstract available for this article. Please follow the digital features link under the abstract.SPRINGER HEIDELBERG2026info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21128Diabetes TherapyISSN: 18696953ISSNe: 18696961reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p211282026-06-14T12:41:47Z
dc.title.none.fl_str_mv Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study
title Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study
spellingShingle Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study
Ritzel, R
Basal insulin
GIP
GLP-1 RA
Insulin glargine 300 U/ml
Real-world evidence
Tirzepatide
Type 2 diabetes
title_short Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study
title_full Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study
title_fullStr Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study
title_full_unstemmed Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study
title_sort Real-World Effectiveness of Insulin Glargine 300 U/ml in People with Type 2 Diabetes Previously Treated with Tirzepatide: The DELIVER-T Study
dc.creator.none.fl_str_mv Ritzel, R
Davies, MJ
Hao, LC
Ji, LN
Lintu, MK
Mabunay, A
Mauricio, D
Bailey, T
author Ritzel, R
author_facet Ritzel, R
Davies, MJ
Hao, LC
Ji, LN
Lintu, MK
Mabunay, A
Mauricio, D
Bailey, T
author_role author
author2 Davies, MJ
Hao, LC
Ji, LN
Lintu, MK
Mabunay, A
Mauricio, D
Bailey, T
author2_role author
author
author
author
author
author
author
dc.subject.none.fl_str_mv Basal insulin
GIP
GLP-1 RA
Insulin glargine 300 U/ml
Real-world evidence
Tirzepatide
Type 2 diabetes
topic Basal insulin
GIP
GLP-1 RA
Insulin glargine 300 U/ml
Real-world evidence
Tirzepatide
Type 2 diabetes
description Introduction: Tirzepatide is recommended as a first-line injectable for people with type 2 diabetes (T2D), but there is a paucity of data on the use of basal insulin after tirzepatide in this population. This study aimed to evaluate glycemic control in people with T2D newly intensified with insulin glargine 300 U/ml (Gla-300) who had suboptimal HbA1c after treatment with tirzepatide. Methods: DELIVER-T was a retrospective analysis of the US Optum's Clinformatics (R) Data Mart from January 1, 2022 to August 31, 2024. People with T2D were included if they were insulin na & iuml;ve and were previously treated with tirzepatide and then intensified with Gla-300. The primary analysis (Gla-300 switch/add-on group) included all those with a HbA1c > 7.0% at baseline who either switched from tirzepatide to Gla-300 or who added Gla-300 to tirzepatide. The primary endpoint was the change in HbA1c levels from baseline to 6 months. Secondary endpoints included reaching HbA1c target < 7.0% and any hypoglycemia. Results: In total, 82 people had a HbA1c > 7.0% at baseline and were included in the primary analysis (Gla-300 switch/add-on group). The mean (SD) change in HbA1c from baseline to 6 months was - 1.3% (2.0; p = 0.0027) for the primary analysis (Gla-300 switch/add-on group). The proportion of participants reaching the target of HbA1c < 7.0% at 6 months was 26.8% (n = 22) for the primary analysis (Gla-300 switch/add-on group). No hypoglycemic events were captured in the database during the 6-month follow-up period. Conclusions: In insulin-na & iuml;ve people with T2D who had suboptimal HbA1c with tirzepatide, significant reductions in HbA1c and improvements in the percentage of people reaching HbA1c target of < 7.0% were observed with Gla-300. Infographic and video abstract available for this article. Please follow the digital features link under the abstract.
publishDate 2026
dc.date.none.fl_str_mv 2026
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21128
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=21128
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SPRINGER HEIDELBERG
publisher.none.fl_str_mv SPRINGER HEIDELBERG
dc.source.none.fl_str_mv Diabetes Therapy
ISSN: 18696953
ISSNe: 18696961
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869425125051334657
score 15.812429

Similares en LA Referencia